Profile data is unavailable for this security.
About the company
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
- Revenue in USD (TTM)17.50m
- Net income in USD-58.88m
- Incorporated2019
- Employees42.00
- LocationLENZ Therapeutics Inc201 Lomas Santa Fe Drive, Suite 300SOLANA BEACH 92075United StatesUSA
- Phone+1 (858) 925-7000
- Fax+1 (302) 655-5049
- Websitehttps://lenz-tx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absci Corp | 2.82m | -114.60m | 386.45m | 156.00 | -- | 1.83 | -- | 137.28 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 388.66m | 104.00 | 20.04 | 5.49 | 18.33 | 3.12 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Ginkgo Bioworks Holdings Inc | 170.16m | -312.76m | 394.79m | 485.00 | -- | 0.7668 | -- | 2.32 | -5.64 | -5.64 | 3.07 | 8.74 | 0.1363 | -- | 7.29 | 350,835.10 | -25.05 | -66.61 | -27.27 | -72.83 | 72.39 | 66.71 | -183.81 | -395.48 | -- | -- | 0.00 | -- | -25.06 | 17.29 | 42.83 | -- | -33.24 | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 396.26m | 106.00 | -- | 2.51 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Upstream Bio Inc | 2.80m | -122.77m | 397.72m | 52.00 | -- | 1.05 | -- | 142.10 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 401.52m | 27.00 | -- | 7.78 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 408.25m | 82.00 | 8.68 | 0.7739 | 6.20 | 1.65 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 409.11m | 140.00 | -- | 1.12 | -- | 3.61 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 411.46m | 42.00 | -- | -- | -- | 23.51 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 413.58m | 60.00 | -- | -- | -- | 81.83 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 425.05m | 18.00 | -- | 32.58 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 431.53m | 227.00 | -- | 1.07 | -- | 3,596.06 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 434.63m | 34.00 | -- | 3.43 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 435.32m | 70.00 | -- | 19.75 | -- | 40.25 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
Data as of Mar 03 2026. Currency figures normalised to LENZ Therapeutics Inc's reporting currency: US Dollar USD
62.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 4.18m | 13.36% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 3.70m | 11.83% |
| Alpha Wave Global LPas of 31 Dec 2025 | 3.61m | 11.54% |
| UBS Securities LLCas of 31 Dec 2025 | 1.57m | 5.02% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.47m | 4.69% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.16m | 3.70% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 1.10m | 3.50% |
| Point72 Asset Management LPas of 31 Dec 2025 | 1.02m | 3.25% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 994.01k | 3.18% |
| Tang Capital Management LLCas of 31 Dec 2025 | 865.17k | 2.77% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
